CHICAGO, March 1, 2005 (PRIMEZONE) -- The Wexler Firm LLP today announced that the U. S. District Court of Southern Ohio has certified a class action lawsuit filed against Wyeth (NYSE:WYE), maker of Premarin(tm), a popular hormone therapy drug used to treat vasomotor symptoms of menopause. Since its approval by the FDA in 1942, the drug has been used by millions of women in the United States alone. Since 1997, Wyeth has sold more than $1 billion worth of the drug.
The class action lawsuit alleges that Wyeth willfully engaged in practices that ultimately resulted in inflated pricing of Premarin. On February 2, 2005, the Court gave the plaintiffs in Ferrell, et al vs. Wyeth-Ayerst Laboratories until March 4, 2005 to identify additional plaintiffs in the following states: Arizona, California, Florida, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Nevada, New Mexico, North Carolina, North Dakota, South Dakota, Tennessee, Vermont, West Virginia and Wisconsin. Those persons include all purchasers of the drug who, from 1999 to the present, either paid for the drug out-of-pocket or paid a percentage co-payment, but does not include purchasers who made a flat co-payment for the drug.
More information on this and other class actions can be found on the Class Action Newsline at www.primezone.com/ca